Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.
Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.
RMD Open. 2021 Sep;7(3). doi: 10.1136/rmdopen-2021-001814.
We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.
From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.
We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.
Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.
我们描述了接受 COVID-19 疫苗的成人系统性风湿病患者的早期经验。
从 2021 年 4 月 2 日至 4 月 30 日，我们对接受 COVID-19 疫苗接种的成人系统性风湿病患者进行了一项在线国际调查。我们收集了患者报告的数据，内容涉及临床医生在接种疫苗前后关于停止疾病修饰抗风湿药物（DMARD）的沟通、信念和意图，以及接种疫苗后的患者报告的不良事件。
我们分析了 2860 名接受 COVID-19 疫苗接种的成人系统性风湿病患者（平均年龄 55.3 岁，86.7%为女性，86.3%为白人）。COVID-19 疫苗的类型为辉瑞-生物技术公司（53.2%）、牛津/阿斯利康（22.6%）、Moderna（21.3%）、杨森/强生（1.7%）和其他（1.2%）。最常见的风湿病是类风湿关节炎（42.3%），81.2%的患者正在服用 DMARD。大多数（81.9%）报告与临床医生就疫苗接种进行了沟通。大多数（66.9%）愿意暂时停止 DMARD 以提高疫苗效力，尽管许多（44.3%）担心风湿病发作。接种疫苗后，最常见的患者报告的不良事件是疲劳/嗜睡（33.4%）、头痛（27.7%）、肌肉/关节疼痛（22.8%）和发热/寒战（19.9%）。需要药物改变的风湿病发作发生在 4.6%的患者中。
在接受 COVID-19 疫苗接种的成人系统性风湿病患者中，患者报告的不良事件与一般人群报告的不良事件相似。大多数患者愿意暂时停止 DMARD 以提高疫苗效力。风湿病发作需要药物治疗的频率相对较低令人放心。
